These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 30226443)
41. The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. Robie DK; Dinauer CW; Tuttle RM; Ward DT; Parry R; McClellan D; Svec R; Adair C; Francis G J Pediatr Surg; 1998 Jul; 33(7):1134-8; discussion 1139-40. PubMed ID: 9694109 [TBL] [Abstract][Full Text] [Related]
42. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses. Dennis K; Hay JH; Wilson DC Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464 [TBL] [Abstract][Full Text] [Related]
43. Usefulness of Stereotactic Radiotherapy Using the CyberKnife for Patients with Inoperable Locoregional Recurrences of Differentiated Thyroid Cancer. Ishigaki T; Uruno T; Tanaka T; Ogimi Y; Masaki C; Akaishi J; Hames KY; Yabuta T; Suzuki A; Tomoda C; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Sugino K; Ito K World J Surg; 2019 Feb; 43(2):513-518. PubMed ID: 30267291 [TBL] [Abstract][Full Text] [Related]
44. Clinical outcome in differentiated thyroid carcinoma and microcarcinoma. Lupoli R; Cacciapuoti M; Tortora A; Barba L; Verde N; Romano F; Vastarella M; Fonderico F; Masone S; Milone M; Lupoli G; Lupoli GA Int J Surg; 2014; 12 Suppl 1():S148-51. PubMed ID: 24859408 [TBL] [Abstract][Full Text] [Related]
45. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Nahas Z; Goldenberg D; Fakhry C; Ewertz M; Zeiger M; Ladenson PW; Wahl R; Tufano RP Laryngoscope; 2005 Feb; 115(2):237-43. PubMed ID: 15689742 [TBL] [Abstract][Full Text] [Related]
46. Significance of Size of Persistent/Recurrent Central Nodal Disease on Surgical Morbidity and Response to Therapy in Reoperative Neck Dissection for Papillary Thyroid Carcinoma. Lang BH; Shek TW; Chan AO; Lo CY; Wan KY Thyroid; 2017 Jan; 27(1):67-73. PubMed ID: 27750029 [TBL] [Abstract][Full Text] [Related]
47. Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease. Hirsch D; Gorshtein A; Robenshtok E; Masri-Iraqi H; Akirov A; Duskin Bitan H; Shimon I; Benbassat C J Clin Endocrinol Metab; 2018 Feb; 103(2):469-476. PubMed ID: 29126111 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081 [TBL] [Abstract][Full Text] [Related]
49. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Trybek T; Kowalska A; Lesiak J; Młynarczyk J Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108 [TBL] [Abstract][Full Text] [Related]
50. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
52. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. Lee JW; Lee SM; Lee DH; Kim YJ J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775 [TBL] [Abstract][Full Text] [Related]
53. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
54. Evaluating the influence of prophylactic central neck dissection on TNM staging and the recurrence risk stratification of cN0 differentiated thyroid carcinoma. Lin X; Chen X; Jiru Y; Du J; Zhao G; Wu Z Bull Cancer; 2016 Jun; 103(6):535-40. PubMed ID: 27236850 [TBL] [Abstract][Full Text] [Related]
55. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. Kukulska A; Krajewska J; Kołosza Z; Paliczka-Cies Lik E; Puch Z; Gubała E; Król A; Kalemba M; Kropin Ska A; Jarząb B Eur J Endocrinol; 2016 Nov; 175(5):379-85. PubMed ID: 27511823 [TBL] [Abstract][Full Text] [Related]
57. Practical Initial Risk Stratification Based on Lymph Node Metastases in Pediatric and Adolescent Differentiated Thyroid Cancer. Jeon MJ; Kim YN; Sung TY; Hong SJ; Cho YY; Kim TY; Shong YK; Kim WB; Kim SW; Chung JH; Kim TH; Kim WG Thyroid; 2018 Feb; 28(2):193-200. PubMed ID: 29179646 [TBL] [Abstract][Full Text] [Related]
58. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784 [TBL] [Abstract][Full Text] [Related]